An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancer
Steven Feins(Parker Institute for Cancer Immunotherapy), Joseph A. Fraietta(University of Pennsylvania)
Cited by 608
Related Papers
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
|Nature Medicine|2024|254
FOXO1 is a master regulator of memory programming in CAR T cells
|Nature|2024|189
Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells
|Immunity|2023|164
BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion
|Science Translational Medicine|2022|126